Ansun Biopharmaincis A Clinical Stage Biopharmaceutical Company Based In San Diegocaliforniafounded In 2003The Company Is Dedicated To Developing Innovative Therapeutics For Severe Viral Infectionsparticularly Targeting Respiratory Viruses With Unmet Treatment Needsansun Focuses On Host Cell Mechanisms To Address Challenges Such As Viral Mutation And Vaccine Evasion The Company S Key Productdas181Is A Recombinant Fusion Protein Designed To Remove Sialic Acid Receptors From Respiratory Cellstargeting Viruses Like Influenza A B And Parainfluenzadas181 Is Currently In Phase 3 Clinical Trials For Use In Immunocompromised Patientssuch As Transplant Recipientsansun S Research Emphasizes The Development Of Host Targeted Antiviral Therapiesmaintaining High Ethical Standards In Its Operationsthe Team Consists Of Experienced Scientists And Industry Veteransled By Ceo Drnancy Chang
